Latest Safety News

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.

AXP Energy has completed and commissioned its first vertical well in Oklahoma, initiating gas sales while raising over A$1 million to fund further development. The company is pivoting its gas-to-power strategy towards Oklahoma after a limited trial in Colorado.

RBR Group Limited reports a significant uptick in tender opportunities exceeding US$80 million following the restart of major LNG projects in Mozambique, alongside steady contract revenues and ongoing infrastructure investments.

PARKD Limited has commissioned its new prefabrication facility in Penrith, successfully delivered a pilot project with McNab Group, and secured $1 million in capital to fuel its east-coast growth strategy.

Vulcan Energy Resources has locked in a €2.2 billion financing package to propel its Phase One Lionheart lithium and renewable energy project in Germany, marking a major step towards Europe’s first fully domestic sustainable lithium supply chain.

Kinetiko Energy reports robust gas production from test wells and secures a binding joint development agreement with FFS Refiners to advance a pilot LNG plant in South Africa, backed by a $3.15 million capital raise and new North American market listing.

Macro Metals Limited has advanced its strategic position by securing export access at Utah Point and acquiring a 27.3% stake in the Extension Iron Ore project, setting the stage for growth in FY26.

Constellation Technologies has broadened its IoT deployments into defence and healthcare sectors while improving its cash flow position in the December quarter.

Clarity Pharmaceuticals reports robust progress in prostate cancer and neuroendocrine tumour trials alongside a strong cash position of $226.2 million, underpinning its path towards commercialisation.

Bathurst Resources reported a first-half FY26 EBITDA of NZD 16 million, maintaining its full-year guidance despite export challenges and cost pressures. Key development projects in New Zealand and Canada continue to advance steadily.

Actinogen Medical has completed enrolment for its pivotal XanaMIA Alzheimer's trial ahead of schedule, with a positive interim analysis supporting continuation. The company is gearing up for an open-label extension and advancing commercial and partnership strategies.

Andromeda Metals has made significant strides in advancing its Great White and High Purity Alumina projects, underpinned by a $14 million capital raise and the commencement of Early Works at the Great White site.